The estimated Net Worth of Lisa Peraza is at least $103 Tisíc dollars as of 13 January 2024. Ms. Peraza owns over 1,841 units of Heron Therapeutics Inc stock worth over $102,560 and over the last 4 years she sold HRTX stock worth over $0. In addition, she makes $0 as Chief Accounting Officer a Vice President at Heron Therapeutics Inc.
Sign up
Ms. Peraza HRTX stock SEC Form 4 insiders trading
Lisa has made over 13 trades of the Heron Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 1,841 units of HRTX stock worth $3,332 on 13 January 2024.
The largest trade she's ever made was exercising 45,115 units of Heron Therapeutics Inc stock on 25 July 2023 worth over $81,658. On average, Lisa trades about 3,698 units every 61 days since 2020. As of 13 January 2024 she still owns at least 56,663 units of Heron Therapeutics Inc stock.
You can see the complete history of Ms. Peraza stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lisa Peraza biography
Lisa Peraza serves as Chief Accounting Officer, Vice President of the Company. Ms. Peraza joined the Company in 2014 and has served as Vice President, Controller since 2019.
How old is Lisa Peraza?
Lisa Peraza is 44, she's been the Chief Accounting Officer a Vice President of Heron Therapeutics Inc since 2020. There are 20 older and no younger executives at Heron Therapeutics Inc. The oldest executive at Heron Therapeutics Inc is Dr. Barry D. Quart, 64, who is the Chairman & CEO.
What's Lisa Peraza's mailing address?
Lisa's mailing address filed with the SEC is 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121.
Insiders trading at Heron Therapeutics Inc
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over $96,663,574 worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth $56,275,132 . The most active insiders traders include Kevin Ctang Capital Managem..., Adam Morgan a Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $176,989. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth $24,973.
What does Heron Therapeutics Inc do?
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
What does Heron Therapeutics Inc's logo look like?
Complete history of Ms. Peraza stock trades at Heron Therapeutics Inc
Heron Therapeutics Inc executives and stock owners
Heron Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barry Quart,
Chairman of the Board, Chief Executive Officer -
John Poyhonen,
President and Chief Commercial Officer -
Kimberly Manhard,
Executive Vice President - Drug Development, Director -
Dr. Barry D. Quart,
Chairman & CEO -
Kimberly J. Manhard,
Exec. VP of Drug Devel. & Director -
John W. Poyhonen,
Pres & Chief Commercial Officer -
David L. Szekeres,
Exec. VP & COO -
Stephen Davis,
Independent Director -
Craig Johnson,
Lead Independent Director -
Christian Waage,
Independent Director -
Lisa Peraza,
Chief Accounting Officer, Vice President -
John Arthur,
Vice President - Manufacturing and Supply -
Sean Ristine,
Vice President - Human Resources -
Christopher Storgard,
Chief Medical Officer -
Thomas Ottoboni,
Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer -
Michael Mathews,
Senior Vice President - Pain Franchise -
Anita Gupta,
Senior Vice President - Medical Strategy and Government Affairs -
David Szekeres,
Chief Operating Officer, Executive Vice President -
Dr. Chris M. Storgard,
Chief Medical Officer -
Michael E. Mathews,
Sr. VP of Acute Care -
Dr. Thomas B. Ottoboni,
Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences -
Sean T. Ristine,
Sr. VP of HR -
Sharmila Dissanaike,
Director -
Paul Marshall,
SVP, Technical Operations -
Robert Rosen,
President -
Kevin Ctang Capital Managem...,
-
Brian G. Drazba,
VP, Finance & CFO -
Robert Hoffman,
CFO & SVP, Finance -
Kevin C Tang,
Director -
Mark S. Md Gelder,
SVP & Chief Medical Officer -
Neil James Clendeninn,
SVP & Chief Medical Officer -
Susan Rodriguez,
Director -
Adam Morgan,
Director -
Craig A Collard,
Chief Executive Officer -
William P Forbes,
EVP, Chief Development Officer -
Ira Duarte,
EVP, Chief Financial Officer